Editorial companion

What stands out

Moderna's 177% pop after a joint melanoma vaccine result with Merck was the kind of headline that rewrites intraday leaderboards, while Target hitting two-year highs and Estée Lauder jumping on earnings made the session feel like a two-act play: biotech fireworks and retail reassurance. Schwab Network walked viewers through those opposite forces, binary clinical wins versus steady consumer beats, and highlighted how a single trial result can overwhelm a longer, weaker track record. For disciplined investors, that gap between headlines and fundamentals is where risk management earns its keep.